Acomplia

INTRODUCTION Obesity and related cardiometabolic derangements are spiraling global health problems urgently in need of safe… Expand

Acomplia was ordered over the internet resulting in the delivery of counterfeit Acomplia and imitation products. The tablets were… Expand

Effective prophylaxis for post-traumatic epilepsy currently does not exist, and clinical trials using anticonvulsant drugs have… Expand

The CB1 inverse agonist/antagonist SR141716A recently has been introduced for the management of obesity (rimonabant; Acomplia… Expand

BACKGROUND AND PURPOSE Rimonabant (Acomplia, SR141716A), a cannabinoid CB1 receptor inverse agonist, has recently been approved… Expand

A meta-analysis of all randomised controlled trials examining the efficacy and safety of the anti-obesity agent Rimonabant… Expand

Rimonabant (SR141716, Acomplia) has been described as an antagonist/inverse agonist at the cannabinoid receptor type 1 (CB1). It… Expand

It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory… Expand

Over past centuries, Cannabis sativa (Delta(9)-tetrahydrocannabinol being the principal active ingredient) has been used… Expand

The endocannabinoid system plays a major role in the regulation of body energy by stimulation of the appetite in the hypothalamus… Expand